"name","uuid:ID","instanceType","description","label","id","rationale"
"Study Design 1","8ec8524f-9e27-49a9-899a-d37229fb7506","StudyDesign","The main design for the study","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
